CERE - Cerevel Therapeutics GAAP EPS of -$0.63 beats by $0.06
2023-08-02 06:41:53 ET
- Cerevel Therapeutics press release ( NASDAQ: CERE ): Q2 GAAP EPS of -$0.63 beats by $0.06 .
- Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025
For further details see:
Cerevel Therapeutics GAAP EPS of -$0.63 beats by $0.06